From the design to the clinical application of thromboxane modulators

Current Pharmaceutical Design

Volumn 12, Issue 8, 2006, Pages 903-923

  Dogné, Jean Michel ^a   Hanson, Julien ^a   de Leval, Xavier ^a   Pratico, Domenico ^b   Pace Asciak, Cecil R ^c   Drion, Pierre ^a   Pirotte, Bernard ^a   Ruan, Ke He ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

GP IIb IIIa binding sites; ICAM 1; Isoprostanes; Prostaglandin; Thrombosis; Thromboxane synthase

Indexed keywords

15 CYCLOPENTYL 14 OXO 13 AZA 16,17,18,19,20 PENTANORPINANE THROMBOXANE A2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [4 (3 PYRIDYLMETHYL)PHENYL]METHACRYLIC ACID; 4,5 DIHYDRO 2 (1H IMIDAZOL 1 YLMETHYL) 6 BENZO[B]THIOPHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ARACHIDONIC ACID; CAMONAGREL; DAZOXIBEN; DOMITROBAN; FUREGRELATE; IFETROBAN; ISBOGREL; OZAGREL; PIRMAGREL; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN ENDOPEROXIDE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR STIMULATING AGENT; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; UNINDEXED DRUG; VAPIPROST;

ANGIOGENESIS; ASTHMA; ATHEROSCLEROSIS; BIOTRANSFORMATION; BRONCHOSPASM; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG DESIGN; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; LUNG DISEASE; LUNG EMBOLISM; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SEPTIC SHOCK; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; VASOCONSTRICTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; DIABETIC RETINOPATHY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION; PROSTAGLANDINS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 33645984877     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055921     Document Type: Review

References (267)

1. Svensson J, Hamberg M, Samuelsson B. On the formation and effects of thromboxane A2 in human platelets. Acta Physiol Scand 1976; 98: 285-94.
2. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990; 81: 169-78; discussion 179-80.
3. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331.
4. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
5. Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR. Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 329-35.
6. Pakala R, Benedict CR. Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med 1998; 131: 527-37.
7. Grosser T, Zucker TP, Weber AA, Schulte K, Sachinidis A, Vetter H, et al. Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol 1997; 319: 327-32.
8. Dorn GW, 2nd Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 1997; 48: 42-62.
9. Dogne JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclin modulators. Curr Med Chem 2000; 7: 609-28.
10. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
11. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
12. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10: 998-1006.
13. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001; 14: 178S-185S.
14. Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1985; 152: 335-40.
15. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol 1988; 71: 122-37.
16. Saldeen TG, Saldeen P, Nichols WW, Lawson DL, Nicolini FA, Mehta JL. Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am Heart J 1993; 125: 277-84.
17. Saldeen P, Nilsson IM, Saldeen T. Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. Thrombi Res 1983; 32: 461-7.
18. Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989; 65: 83-94.
19. Jankov RP, Belcastro R, Ovcina E, Lee J, Massaeli H, Lye SJ, et al. Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. Am J Respir Crit Care Med 2002; 166: 208-14.
20. Dogne JM, de Leval X, Benoit P, Rolin S, Pirotte B, Masereel B. Therapeutic potential of thromboxane inhibitors in asthma. Expert Opin Investig Drugs 2002; 11: 275-81.
21. Matejovic M, Radermacher P, Zulke C, Vlatten A, Altherr J, Brinkmann A, et al Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. Shock 2000; 13: 307-13.
22. Mehta JL, Lawson D, Mehta P, Saldeen T. Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 1988; 85: 4511-5.
23. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclooxygenase products and atherothrombosis. Ann Med 2000; 32 Suppl 1: 21-6.
24. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-6.
25. Kaneko N, Masuyama J, Nara H, Hirata D, Iwamoto M, Okazaki H, et al. Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis. J Rheumatol 2002; 29: 2106-13.
26. Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-8.
27. Reilly IA, Roy L, Fitzgerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) 1986; 292: 1037-9.
28. Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976; 193: 163-5.
29. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976; 261: 558-60.
30. Ellis EF, Oelz O, Roberts LJ, 2nd, Payne NA, Sweetman BJ, Nies AS, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 1976; 193: 1135-7.
31. Pawlowski NA, Kaplan G, Hamill AL, Cohn ZA, Scott WA. Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med 1983; 158: 393-412.
32. Ullrich V, Zou MH, Bachschmid M. New physiological and pathophysiological aspects on the thromboxane A(2)-prostacyclin regulatory system. Biochim.Biophys Acta 2001; 1532: 1-14.
33. Wise H, Wong YH, Jones RL. Prostanoid signal integration and cross talk. Neurosignals 2002; 11: 20-8.
34. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001; 89: 650-60.
35. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
36. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167: 2831-8.
37. Caughey GE, Cleland LG, Gamble JR, James MJ. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001; 276: 37839-45.
38. Roberts LJ, 2nd, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384-93.
39. Bohm E, Sturm GJ, Weiglhofer I, Sandig H, Shichijo M, McNamee A, et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 2004; 279: 7663-70.
40. Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 1985; 260: 15059-67.
41. Uchida K. Current Status of Acrolein as a Lipid Peroxidation product. Trends in Cardiovascular Medicine 1999; 9: 109-113.
42. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow JD, Blair IA, et al. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science 1994; 265: 1580-2.
43. Ruan KH, Wang LH, Wu KK, Kulmacz RJ. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum. J Biol Chem 1993; 268: 19483-90.
44. Hecker M, Ullrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem 1989; 264: 141-50.
45. Wang LH, Tsai AL, Hsu PY. Substrate binding is the rate-limiting step in thromboxane synthase catalysis. J Biol Chem 2001; 276: 14737-43.
46. Miyata A, Yokoyama C, Ihara H, Bandoh S, Takeda O, Takahashi E, et al. Characterization of the human gene (TBXAS1) encoding thromboxane synthase. Eur J Biochem 1994; 224: 273-9.
47. Tazawa R, Green ED, Ohashi K, Wu KK, Wang LH. Characterization of the complete genomic structure of human thromboxane synthase gene and functional analysis of its promoter. Arch Biochem Biophys 1996; 334: 349-56.
48. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-29.
49. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991; 349: 617-20.
50. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002; 68-9: 535-556.
51. Halushka PV. Thromboxane A(2) receptors: where have you gone? Prostaglandins Other Lipid Mediat 2000; 60: 175-89.
52. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 504-8.
53. Knezevic I, Borg C, Le Breton GC. Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/ prostaglandin H2 receptors. J Biol Chem 1993; 268: 26011-7.
54. Kinsella BT, O'Mahony DJ, Fitzgerald GA. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 1997; 281: 957-64.
55. Vezza R, Habib A, FitzGerald GA. Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem 1999; 274: 12774-9.
56. Namba T, Sugimoto Y, Hirata M, Hayashi Y, Honda A, Watabe A, et al. Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun 1992; 184: 1197-203.
57. Blackman SC, Dawson G, Antonakis K, Le Breton GC. The identification and characterization of oligodendrocyte thromboxane A2 receptors. J Biol Chem 1998; 273: 475-83.
58. D'Angelo DD, Terasawa T, Carlisle SJ, Dorn GW 2nd, Lynch KR. Characterization of a rat kidney thromboxane A2 receptor: high affinity for the agonist ligand I-BOP. Prostaglandins 1996; 52: 303-16.
59. Swanson ML, Lei ZM, Swanson PH, Rao CV, Narumiya S, Hirata M. The expression of thromboxane A2 synthase and thromboxane A2 receptor gene in human uterus. Biol Reprod 1992; 47: 105-17.
60. Batshake B, Nilsson C, Sundelin J. Structure and expression of the murine thromboxane A2 receptor gene. Biochem Biophys Res Commun 1999; 256: 391-7.
61. Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, et al. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 1993; 178: 1825-30.
62. Allan CJ, Halushka PV. Characterization of human peripheral blood monocyte thromboxane A2 receptors. J Pharmacol Exp Their 1994; 270: 446-52.
63. Mais DE, Saussy DL Jr, Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N, et al. Pharmacologic characterization of human and canine thromboxane A2/ prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther 1985; 233: 418-24.
64. Mais DE, DeHoll D, Sightler H, Halushka PV. Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels. Eur J Pharmacol 1988; 148: 309-15.
65. Morinelli TA, Niewiarowski S, Daniel JL, Smith JB. Receptor-mediated effects of a PGH2 analogue (U 46619) on human platelets. Am J Physiol 1987; 253: H1035-43.
66. Dorn GW 2nd. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. J Clin Invest 1989; 84: 1883-91.
67. Dorn GW 2nd, DeJesus A. Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors. Am J Physiol 1991; 260: H327-34.
68. Nusing RM, Hirata M, Kakizuka A, Eki T, Ozawa K, Narumiya S. Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem 1993; 268: 25253-9.
69. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994; 269: 19256-61.
70. Qiao N, Reynaud D, Demin P, Halushka PV, Pace-Asciak CR. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells. J Pharmacol Exp Ther 2003; 307: 1142-7.
71. Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 2645-51.
72. Walsh MT, Foley JF, Kinsella BT. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem 2000; 275: 20412-23.
73. Parent JL, Labrecque P, Orsini MJ, Benovic JL. Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 1999; 274: 8941-8.
74. Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 1993; 44: 934-9.
75. Yamamoto Y, Kamiya K, Terao S. Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. J Med Chem 1993; 36: 820-5.
76. Narumiya S, Hirata N, Namba T, Hayashi Y, Ushikubi F, Sugimoto Y, et al. Structure and function of prostanoid receptors. J Lipid Mediat 1993; 6: 155-61.
77. Chiang N, Kan WM, Tai HH. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch Biochem Biophys 1996; 334: 9-17.
78. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW 2nd. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem 1996; 271: 6233-40.
79. Dorn GW 2nd, Davis MG, D'Angelo DD. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J Biol Chem 1997; 272: 12399-405.
80. Ruan KH, So SP, Wu J, Li D, Huang A, Kung J. Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry 2001; 40: 275-80.
81. Turek JW, Halmos T, Sullivan NL, Antonakis K, Le Breton GC. Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J Biol Chem 2002; 277: 16791-7.
82. Halmos T, Turek JW, Le Breton GC, Antonakis K. Synthesis and biological characterization of sqbazide, a novel biotinylated photoaflinity probe for the study of the human platelet thromboxane A2 receptor. Bioorg Med Chem Lett 1999; 9: 2963-8.
83. Albuquerque MG, Hopfinger AJ, Barreiro EJ, de Alencastro RB. Four-dimensional quantitative structure-activity relationship analysis of a series of interphenylene 7-oxabicycloheptane oxazole thromboxane A2 receptor antagonists. J Chem Inf Comput Sci 1998; 38: 925-38.
84. So SP, Wu J, Huang G, Huang A, Li D, Ruan KH. Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem 2003; 278: 10922-7.
85. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd Formation of unique biologically active prostaglandins in vivo by a non-cyclooxygenase free radical catalyzed mechanism. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 125-8.
86. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem 2003; 10: 1723-40.
87. Kearney D, Byrne A, Crean P, Cox D, Fitzgerald DJ. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004; 43: 526-31.
88. Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271: 14916-24.
89. Morrow JD, Minton TA, Roberts LJ, 2nd The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/ endoperoxide receptor antagonist. Prostaglandins 1992; 44: 155-63.
90. Fukunaga M, Makita N, Roberts LJ 2nd, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993; 264: C1619-24.
91. Fukunaga M, Yura T, Grygorczyk R, Badr KF. Evidence for the distinct nature of F2-isoprostane receptors from those of thromboxane A2. Am J Physiol 1997; 272: F477-83.
92. Dogne JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004; 11: 1223-41.
93. Soyka R, Guth BD, Weisenberger HM, Luger P, Muller TH. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J Med Chem 1999; 42: 1235-49.
94. Hamberg M, Svensson J, Wakabayashi T, Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 1974; 71: 345-9.
95. Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 1981; 73: 773-8.
96. Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther 1992; 6: 29-33.
97. Minoguchi K, Adachi M. Thromboxane A2 synthase inhibitor and receptor antagonist. Nippon Rinsho 2001; 59: 1986-91.
98. Patscheke H, Homberger W, Zehender H. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. Z Kardiol 1990; 79 Suppl 3: 151-4.
99. Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81: I12-5; discussion I22-3.
100. Hecker M, Haurand M, Ullrich V, Terao S. Spectral studies on structure-activity relationships of thromboxane synthase inhibitors. Eur J Biochem 1986; 157: 217-23.
101. Kato K, Ohkawa S, Terao S, Terashita Z, Nishikawa K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J Med Chem 1985; 28: 287-94.
102. Dogne JM, De Leval X, Benoit P, Delarge J, Masereel B. Thromboxane a(2) inhibition: therapeutic potential in bronchial asthma. Am J Respir Med 2002; 1: 11-7.
103. Patscheke H, Stegmeier K, Muller-Beckmann B, Sponer G, Staiger C, Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed Biochim Acta 1984; 43: S312-8.
104. Stegmeier K, Pill J, Muller-Beckmann B, Schmidt FH, Witte EC, Wolff HP, et al. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res 1984; 35: 379-95.
105. Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; 1: 991-4.
106. Patscheke H, Stegmeier K. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res 1984; 33: 277-88.
107. Riess H, Hiller E, Reinhardt B, Brauning C. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. Thromb Res 1984; 35: 371-8.
108. Karasawa A, Shirakura S, Higo K, Kubo K. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5, 6-dimethyl-1-benzimidazolyl)-ethylidene]-6, 11- dihydrodibenz[b, e]oxepine-1-carboxylate monohydrate on smooth muscle preparations. Arzneimittelforschung 1991; 41: 1237-41.
109. Miki I, Kase H, Ishii A. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells. Eur J Pharmacol 1992; 227: 199-204.
110. Bertolino F, Valentin JP, Patoiseau JF, Rieu JP, Colpaert FC, John GW. Evidence for partial agonist properties of daltroban (BM 13, 505) at TP receptors in the anaesthetized open-chest rat. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 462-6.
111. Shinozaki K, Sato H, Iwakuma T, Sato R, Kurimoto T, Yoshida K. Synthesis and thromboxane A2 antagonistic activity activity of indane derivatives. Bioorg Med Chem Lett 1999; 9: 401-6.
112. Depin JC, Vigie A, Chavernac G, Rousselot C, Lardy C, Guerrier D. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4- 1 - [(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneac etate. Arzneimittelforschung 1994; 44: 1203-7.
113. Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4- 1- [(4-chlorophenyl) sulfonyl]amino]methyl]cyclope ntyl] methyl]benzenea cetate. Arzneimittelforschung 1994; 44: 1196-202.
114. Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS. HN-11500--a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 1994; 71: 103-9.
115. Cimetiere B, Dubuffet T, Landras C, Descombes JJ, Simonet S, Verbeuren TJ, et al New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. Bioorg Med Chem Lett 1998; 8: 1381-6.
116. Cimetiere B, Dubuffet T, Muller O, Descombes JJ, Simonet S, Laubie M, et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998; 8: 1375-80.
117. Rosentreter U, Boshagen H, Seuter F, Perzborn E, Fiedler VB. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1, 2, 3, 4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer. Arzneimittelforschung 1989; 39: 1519-21.
118. Kanao M, Watanabe Y, Kimura Y, Saegusa J, Yamamoto K, Kanno H, et al. Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. J Med Chem 1989; 32: 1326-34.
119. Fukumoto S, Shiraishi M, Terashita Z, Ashida Y, Inada Y. Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J Med Chem 1992; 35: 2202-9.
120. Kurokawa T, Matsumoto T, Ashida Y, Sasada R, Iwasa S. Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414. Biol Pharm Bull 1994; 17: 383-5.
121. Terao S, Shiraishi M, Matsumoto T, Ashida Y. Thromboxane A2 antagonist--discovery of seratrodast. Yakugaku Zasshi 1999; 119: 377-90.
122. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-45.
123. Dogne JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/ II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 49-54.
124. Dogne JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 2000; 62: 311-7.
125. Dogne JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, et al. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 2001; 19: 87-96.
126. Dogne JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F, et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 2001; 53: 669-80.
127. de Leval X, Benoit V, Delarge J, Julemont F, Masereel B, Pirotte B, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 55-9.
128. Michaux C, Rolin S, Dogne JM, Durant F, Masereel B, Delarge J, et al. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition. Bioorg Med Chem Lett 2001; 11: 1019-22.
129. Pace-Asciak CR, Reynaud D, Demin P, Aslam R, Sun A. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J Pharmacol Exp Ther 2002; 301: 618-24.
130. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309-17.
131. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947-57.
132. Pinsky PF, Hurwitz ES, Schonberger LB, Gunn WJ. Reye's syndrome and aspirin. Evidence for a dose-response effect. JAMA 1988; 260: 657-61.
133. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
134. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-95.
135. Vetrano A, Milani M, Corsini G. Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial. G Ital Cardiol 1999; 29: 524-8.
136. Tanaka T, Ito S, Higashino R, Fukuta Y, Fukuda Y, Takei M, et al. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res 1998; 91: 229-35.
137. Tanaka T, Sato R, Kurimoto T. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur J Pharmacol 2000; 401: 413-8.
138. Matsuno H, Uematsu T, Niwa M, Kozawa O, Nagashima S, Kohno K, et al. Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol 2002; 42: 782-90.
139. Guth BD, Narjes H, Schubert HD, Tanswell P, Riedel A, Nehmiz G. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A receptor and synthase inhibitor, in healthy subjects. Br J Clin Pharmacol 2004; 58: 40-51.
140. Dogne JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, et al. Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methylphenylamino)-5- nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 2004; 309: 498-505.
141. Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B, et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther 2003; 306: 59-65.
142. Osende JI, Shimbo D, Fuster V, Dubar M, Badimon JJ. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 2: 492-8.
143. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-33.
144. Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther 1998; 20 Suppl B: B18-41.
145. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
146. Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996; 42: 782-5.
147. Van Diest MJ, Herman AG, Verbeuren TJ. Influence of hypercholesterolaemia on the reactivity of isolated rabbit arteries to 15-lipoxygenase metabolites of arachidonic acid: comparison with platelet-derived agents and vasodilators. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 135-45.
148. Pfister SL, Schmitz JM, Willerson JT, Campbell WB. Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas. Prostaglandins 1988; 36: 515-32.
149. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998; 4: 1189-92.
150. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
151. Sultana C, Shen Y, Rattan V, Kalra VK. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol 1996; 167: 477-87.
152. Mallat Z, Nakamura T, Ohan J, Leseche G, Tedgui A, Maclouf J, et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999; 103: 421-7.
153. Tesfamariam B, Brown ML, Cohen RA. 15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta. J Cardiovasc Pharmacol 1995; 25: 748-55.
154. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-204.
155. Luscher TF, Boulanger CM, Dohi Y, Yang ZH. Endothelium-derived contracting factors. Hypertension 1992; 19: 117-30.
156. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003; 14: 213-8.
157. Dallinger KJ, Jennings PE, Toop MJ, Gyde OH, Barnett AH. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diabet Med 1987; 4: 44-8.
158. Ishii H, Umeda F, Nawata H. Platelet function in diabetes mellitus. Diabetes Metab Rev 1992; 8: 53-66.
159. Hendra T, Betteridge DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1989; 35: 197-212.
160. Moreno A, De La Cruz JP, Garcia Campos J, Sanchez De La Cuesta F. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can J Ophthalmol 1995; 30: 117-23.
161. Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990; 322: 978-83.
162. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, Sanchez De La Cuesta F. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. Thromb Res 2000; 97: 125-31.
163. Coto V, Oliviero U, Cocozza M, Milani M. Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. J Int Med Res 1998; 26: 200-5.
164. De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sanchez de La Cuesta F. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. Br J Pharmacol 2002; 137: 1082-8.
165. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-203.
166. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-81.
167. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48: 23-33.
168. Klotz TA, Cohn LS, Zipser RD. Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease. Chest 1984; 85: 329-35.
169. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ, 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319: 761-7.
170. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ, 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988; 319: 689-98.
171. Reeves WC, Demers LM, Wood MA, Skarlatos S, Copenhaver G, Whitesell L, et al. The release of thromboxane A2 and prostacyclin following experimental acute pulmonary embolism. Prostaglandins Leukot Med 1983; 11: 1-10.
172. Utsonomiya T, Krausz MM, Levine L, Shepro D, Hechtman HB. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest 1982; 70: 361-8.
173. Johnson A, Malik AB. Pulmonary transvascular fluid and protein exchange after thrombin-induced microembolism. Differential effects of cyclooxygenase inhibitors. Am Rev Respir Dis 1985; 132: 70-6.
174. Perlman MB, Johnson A, Malik AB. Ibuprofen prevents thrombin-induced lung vascular injury: mechanism of effect. Am J Physiol 1987; 252: H605-14.
175. Delcroix M, Melot C, Lejeune P, Leeman M, Naeije R. Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism. Am Rev Respir Dis 1992; 145: 806-10.
176. Hofman WF, Ehrhart IC. Effects of cyclooxygenase inhibition on pulmonary vascular responses to serotonin. J Appl Physiol 1987; 62: 1192-200.
177. Ghuysen A, Lambermont B, Dogne JM, Kolh P, Tchana-Sato V, Morimont P, et al. Effect of BM-573, a dual thromboxane synthase inhibitor and TP receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther 2004.
178. Ogletree ML, Brigham KL. Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins Leukot Med 1982; 8: 489-502.
179. Wise WC, Cook JA, Halushka PV. Implications for thromboxane A2 in the pathogenesis of endotoxic shock. Adv Shock Res 1981; 6: 83-91.
180. Redl G, Abdi S, Traber LD, Nichols RJ, Flynn JT, Hemdon DN, et al Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Crit Care Med 1991; 19: 1294-302.
181. Mikashima H, Muramoto Y. Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. Thromb Res 1990; 57: 499-505.
182. Jesmok G, Gundel R. Thromboxane-blocked swine as an experimental model of severe intravascular inflammation and septic shock. Shock 1995; 4: 379-83.
183. Altavilla D, Canale P, Squadrito F, Sardella A, Ammendolia L, Uma G, et al. Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock. Pharmacol Res 1994; 30: 137-51.
184. Lambermont B, Kolh P, Ghuysen A, Segers P, Dogne JM, Tchana-Sato V, et al. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock 2004; 21: 45-51.
185. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283: R29-45.
186. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 223-32.
187. Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, et al. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 2001; 38: 803-8.
188. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull 2003; 67: 161-76.
189. Svane D, Skajaa K, Andersson KE, Forman A. Effects of the thromboxane-receptor antagonists AH 23848 and BM 13.177 on human uteroplacental arteries. Obstet Gynecol 1992; 80: 234-40.
190. Keith JC, Jr., Miller K, Eggleston MK, Kutruff J, Howerton T, Konczal C, et al Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension. Am J Obstet Gynecol 1989; 161: 1305-13.
191. Furuhashi N, Tsujiei M, Kimura H, Okamura K, Yajima A. Antithromboxane drug in the treatment of preeclampsia. Gynecol Obstet Invest 1991; 32: 164-6.
192. Keith JC, Jr., Spitz B, Van Assche FA. Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview. Prostaglandins 1993; 45: 3-13.
193. Furuhashi N, Tsujiei M, Kimura H, Nagae H, Yajima A. Effects of thromboxane synthetase inhibitor (OKY-046) on placental blood flow, placental weight and fetal weight in normotensive and spontaneously hypertensive rats. Gynecol Obstet Invest 1993; 35: 23-6.
194. Seki H, Kuromaki K, Takeda S, Kinoshita K, Satoh K. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens Pregnancy 1999; 18: 157-64.
195. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17: 3S-12S.
196. Devillier P, Bessard G. Thromboxane A2 and related prostaglandins in airways. Fundam Clin Pharmacol 1997; 11: 2-18.
197. Beasley RC, Featherstone RL, Church MK, Rafferty P, Varley JG, Harris A, et al. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol 1989; 66: 1685-93.
198. Nakazawa M, Iizuka K, Ujiie A, Hiraku S, Ohki S. Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase. Yakugaku Zasshi 1994; 114: 911-33.
199. Ueno A, Tanaka K, Katori M. Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs. Prostaglandins 1982; 23: 865-80.
200. Fujimura M, Miyake Y, Uotani K, Kanamori K, Matsuda T. Secondary release of thromboxane A2 in aerosol leukotriene C4-induced bronchoconstriction in guinea pigs. Prostaglandins 1988; 35: 427-35.
201. Nambu F, Shiraji T, Motoishi M, Sawada M, Omawari N, Terashima H, et al. Effect of an oral thromboxane synthetase inhibitor (OKY-046) on antigen-induced bronchoconstriction in guinea pigs. Adv Prostaglandin Thromboxane Leukot Res 1989; 19: 528-30.
202. Nambu F, Yube N, Omawari N, Sawada M, Okegawa T, Kawasaki A, et al. Inhibition of endothelin-induced bronchoconstriction by OKY-046, a selective thromboxane A2 synthetase inhibitor, in guinea pigs. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 453-6.
203. Sakurai T, Yamaguchi S, Iwama T, Nagai H. Pharmacological studies of platelet-activating factor (PAF)-induced augmentation of response to histamine in guinea-pigs. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 95-9.
204. Saito M, Fujimura M, Sakamoto S, Miyake Y, Shintani H, Yasui M, et al. Involvement of arachidonate cyclooxygenase products in bronchial hyperresponsiveness induced by subthreshold concentration of aerosolized thromboxane A2 analogue (STA2) in guinea pigs. Allergy 1992; 47: 181-4.
205. Chung KF, Aizawa H, Becker AB, Frick O, Gold WM, Nadel JA. Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs. Am Rev Respir Dis 1986; 134: 258-61.
206. Komatsu H, Takehana Y, Kikuchi S, Kojima M, Hamano S, Kusama H, et al. Effect of a thromboxane A2 synthetase inhibitor (OKY-046.HC1) on airway hyperresponsiveness in guinea pigs. Eur J Pharmacol 1990; 184: 87-95.
207. Sato T, Iwama T, Shikada K, Tanaka S. Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Clin Exp Allergy 1996; 26: 957-63.
208. Fujimura M, Sakamoto S, Matsuda T. Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. Chest 1990; 98: 656-60.
209. Fujimura M, Sasaki F, Nakatsumi Y, Takahashi Y, Hifumi S, Taga K, et al. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 1986; 41: 955-9.
210. Fujimura M, Nishioka S, Kumabashiri I, Matsuda T, Mifune J. Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. Chest 1990; 98: 276-9.
211. Tokiyoshi K, Ohnishi T, Nii Y. Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol 1991; 36: 112-8.
212. Itoh H, Yamatani K, Oshida N, Shioi M, Takaba M, Kamiyama H, et al. Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery. No To Shinkei 1998; 50: 147-55.
213. Ishitsuka Y, Moriuchi H, Hatamoto K, Yang C, Takase J, Golbidi S, et al. Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. J Pharm Pharmacol 2004; 56: 513-20.
214. Ashida Y, Matsumoto T, Kuriki H, Shiraishi M, Kato K, Tersao, S. A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 1989; 38: 91-112.
215. Shiraishi M, Kato K, Terao S, Ashida Y, Terashita Z, Kito G. Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation. J Med Chem 1989; 32: 2214-21.
216. Matsumoto T, Ashida Y, Tsukuda R. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig. J Pharmacol Exp Ther 1994; 269: 1236-44.
217. Imai T, Adachi M, Idaira K, Suganuma T, Takahashi T, Yamaguchi H, et al. The effect of a specific thromboxane A2 antagonist, AA-2414 on airway hyperresponsiveness induced by ozone exposure in dogs. Arerugi 1991; 40: 28-36.
218. Matsumoto T, Ashida Y. Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane A2 receptor antagonist (AA-2414) in Ascaris suum-allergic dogs. Prostaglandins 1993; 46: 301-18.
219. Norel X, Labat C, Gardiner PJ, Brink C. Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br J Pharmacol 1991; 104: 591-5.
220. Norel X, Labat C, Gardiner P, Brink C. Prostanoid contractions in human isolated pulmonary muscle preparations: inhibition by BAY u3405. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 473-6.
221. McKenniff MG, Norman P, Cuthbert NJ, Gardiner PJ. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. Br J Pharmacol 1991; 104: 585-90.
222. Norman P, Cuthbert NJ, Gardiner PJ, McKenniff MG. BAY u3405 is a potent and competitive antagonist of U46619, PGD2 and 9 alpha, 11 beta PGF2 alpha-induced contractions of airway smooth muscle. Ann N Y Acad Sci 1991; 629: 396-8.
223. Francis HP, Morris TG, Thompson AM, Patel UP, Gardiner PJ. The thromboxane receptor antagonist BAY u3405 reverses prostaglandin D2 (PGD2)-induced bronchoconstriction in the anaesthetised guinea pig. Ann N Y Acad Sci 1991; 629: 399-401.
224. Iwamoto I, Umibe T, Nakajima H, Yoshida S. Effect of a selective thromboxane A2 receptor antagonist BAY u3405 on antigen-, leukotriene C4- and leukotriene D4-induced bronchoconstriction in guinea pigs. Int Arch Allergy Immunol 1995; 108: 68-73.
225. Magnussen H, Boerger S, Templin K, Baunack AR. Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 1119-26.
226. Rajakulasingam K, Johnston SL, Ducey J, Ritter W, Howarth PH, Holgate ST. Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. J Appl Physiol 1996; 80: 1973-7.
227. Aizawa H, Shigyo M, Nogami H, Hirose T, Hara N. BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest 1996; 109: 338-42.
228. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003; 305: 347-52.
229. Ishizuka T, Matsui T, Okamoto Y, Ohta A, Shichijo M. Ramatroban (BAY u 3405): A Novel Dual Antagonist of TXA2 Receptor and CRTh2, a Newly Identified Prostaglandin D2 Receptor. Cardiovasc Drug Rev 2004; 22: 71-90.
230. Cardoso CR, de Brito FC, da Silva KC, de Miranda AL, Fraga CA, Barreiro EJ. Design, synthesis and pharmacological evaluation of novel pyrazolo[3, 4-b]thieno[2, 3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorg Med Chem Lett 2002; 12: 9-12.
231. Arakida Y, Suwa, K, Ohga K, Yokota M, Miyata K, Yamada T, et al. In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther 1998; 287: 633-9.
232. Arakida Y, Ohga K, Kobayashi S, Yokota M, Miyata K, Yamada T, et al. Binding of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors, to guinea pig lung membranes. Eur J Pharmacol 1998; 362: 229-33.
233. Arakida Y, Ohga K, Suwa K, Okada Y, Morio H, Yokota M, et al. Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs. Jpn J Pharmacol 2000; 82: 287-94.
234. Arakida Y, Ohga K, Suwa K, Okada Y, Morio H, Yokota M, et al. In vivo pharmacologic profile of YM158, anew dual antagonist for leukotriene D4 and thromboxane A2 receptors. Jpn J Pharmacol 2000; 83: 63-72.
235. Komatsu Y, Minami N. Synthesis of a novel dual inhibitor of thromboxane A2 synthetase and 5-lipoxygenase (E3040) via the direct coupling reaction of hydroquinone with 3-pyridinecarboxaldehyde. Chem Pharm Bull (Tokyo) 1995; 43: 1614-6.
236. Oketani K, Nagakura N, Harada K, Inoue T. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production. Eur J Pharmacol 2001; 422: 209-16.
237. Sakai H, Suzuki T, Murota M, Oketani K, Uchiumi T, Murakami M, et al. E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the C1- secretion induced by platelet-activating factor in isolated rat colon. Br J Pharmacol 2002; 136: 383-90.
238. Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T. Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice. Biopharm Drug Dispos 1999; 20: 271-6.
239. Oketani K, Inoue T, Murakami M. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide. Eur J Pharmacol 2001; 427: 159-66.
240. Hwang TL, Yeh YA, Chern JW, Teng CM. Pharmacological characterization of EK112, a new combined angiotensin II and thromboxane A(2) receptor antagonist. Gen Pharmacol 2000; 34: 25-31.
241. Jacobs C, Frotscher M, Dannhardt G, Hartmann RW. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. J Med Chem 2000; 43: 1841-51.
242. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 2004; 11: 1243-52.
243. Miyamoto M, Yamada N, Ikezawa S, Ohno M, Otake A, Umemura K, et al. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol 2003; 140: 889-94.
244. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-4.
245. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004; 31: 64-73.
246. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62: 1676-81.
247. Yoshimatsu K, Altorki NY, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001; 7: 2669-74.
248. Taketo MM. COX-2 and colon cancer. Inflamm Res 1998; 47 Suppl 2: S112-6.
249. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F, et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002; 94: 1565-73.
250. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21: 1291-4.
251. McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA, et al Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988; 48: 3140-7.
252. Pinto S, Gori L, Gallo O, Boccuzzi S, Paniccia R, Abbate R. Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 527-30.
253. Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P, et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989; 49: 1505-8.
254. Nanji AA. Thromboxane synthase and organ preference for metastases. N Engl J Med 1993; 329: 138-9.
255. Kurzel F, Hagel C, Zapf S, Meissner H, Westphal M, Giese A. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurochir (Wien) 2002; 144: 71-87.
256. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 2001; 15: 1517-28.
257. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 2003; 22: 7716-27.
258. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, et al. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 2000; 267: 245-51.
259. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-7.
260. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002; 62: 63-6.
261. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-18.
262. Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980; 77: 4336-9.
263. Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992; 18: 392-415.
264. Mehta P, Lawson D, Ward MB, Lee-Ambrose L, Kimura A. Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Res 1986; 46: 5061-3.
265. Claria J. Cyclooxygenase-2 biology. Curr Pharm Design 2003; 9(27): 2177-90.
266. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Design 2004; 10(6): 577-88.
267. Skelly MM, Hawkey CJ. Dual COX inhibition and upper gastrointestinal damage. Curr Pharm Design 2003; 9(27): 2191-5.